openPR Logo
Press release

Tyrosine Kinase Inhibitors Market Key Trends and Growth Drivers in Targeted Therapy | Key Players: Bayer Corporation, F. Hoffmann-La Roche Ltd, AstraZeneca, Novartis AG

01-16-2025 12:41 PM CET | Health & Medicine

Press release from: DataM intelligence 4 Market Research LLP

Tyrosine Kinase Inhibitors Market

Tyrosine Kinase Inhibitors Market

Tyrosine Kinase Inhibitors Market reached US$ 51.03 billion in 2023 and is expected to reach US$ 82.47 billion by 2031, growing at a CAGR of 6.3% during the forecast period 2024-2031.

Tyrosine Kinase Inhibitors Market analysis, according to DataM Intelligence, offers more than just an overview, it investigates the underlying aspects of the sector. The study provides an overview, the research explores the hidden aspects of the sector, breaking down its intricate dynamics, charting regional dominance, spotting demand patterns, and spotting prospective breakthroughs that could influence how businesses operate in the future.

Get a Free Sample PDF copy of the report - https://datamintelligence.com/download-sample/tyrosine-kinase-inhibitors-market

The Tyrosine Kinase Inhibitors market report majorly focuses on market trends, historical growth rates, technologies, and the changing investment structure. Additionally, the report shows the latest market insights, increasing growth opportunities, business strategies, and growth plans adopted by major players. Moreover, it contains an analysis of current market dynamics, future developments, and Porter's Five Forces Analysis.

Tyrosine kinase inhibitors (TKIs) are a class of drugs that block the activity of enzymes known as tyrosine kinases. Tyrosine kinases are a type of enzyme that plays a critical role in the regulation of cell functions, including cell growth, differentiation, metabolism, and apoptosis (cell death). These enzymes are involved in signaling pathways that control how cells respond to external signals, and when dysregulated, they can lead to various diseases, including cancer.

Forecast Growth Projected:

The Global Tyrosine Kinase Inhibitors Market is anticipated to rise at a considerable rate during the forecast period, between 2024 and 2031. In 2023, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

List of the Key Players in the Tyrosine Kinase Inhibitors Market:

Boehringer Ingelheim International GmbH, Bayer Corporation, F. Hoffmann-La Roche Ltd, AstraZeneca, Novartis AG, Bristol Myers Squibb, Pfizer Inc, Eli Lilly, and Company, Eisai Co., Ltd, and Takeda Pharmaceutical Company Limited among others.

Segment Covered in the Tyrosine Kinase Inhibitors Market:

➧ By Type (BCR-ABL Tyrosine Kinase Inhibitor, Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitors, Receptor Tyrosine Kinase Inhibitor , Non- Receptor Tyrosine Kinase Inhibitors (n RTKI's), Others)
➧ By Application (Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer, Others)
➧ By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others)

Key Developments

In March 2024, Takeda announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for ICLUSIG (ponatinib) for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy.

In March 2024, Novartis AG is in discussions to secure a distribution partner for the imminent launch of Asciminib, the first-in-class treatment for chronic myeloid leukemia (CML) targeting the ABL myristoyl pocket (STAMP). Asciminib is the first tyrosine kinase inhibitor (TKI) to target the ABL1 myristoyl pocket. TKIs are frequently effective in treating CML for prolonged periods.

In February 2024, AstraZeneca's Tagrisso (osimertinib) with the addition of chemotherapy has been approved in the US for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). Approval based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months vs. standard of care.

In January 2024, Novartis announced positive results from the primary analysis of ASC4FIRST, a pivotal Phase III trial comparing Scemblix(asciminib) with investigators' choice of tyrosine kinase inhibitor (TKI) treatment in newly diagnosed patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP).

In January 2024, Bristol Myers Squibb announced that the European Medicines Agency (EMA) has validated its marketing authorization application for the next-generation tyrosine kinase inhibitor (TKI) repotrectinib as a treatment for ROS1 TKI-naïve and -pretreated adult patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) and TKI-naïve and -pretreated adult and pediatric patients 12 years and older with NTRK-positive locally advanced or metastatic solid tumors.

Get this Premium Report: https://www.datamintelligence.com/buy-now-page?report=tyrosine-kinase-inhibitors-market

Regional Break out:

The global Tyrosine Kinase Inhibitors Market report focuses on six major regions: North America, South America, Europe, Asia Pacific, the Middle East, and Africa.

☞ North America - US, Canada, Mexico
☞ Europe- Germany, Russia, UK, France, Italy, Rest of Europe
☞ Asia Pacific- China, India, Japan, Australia, Rest of Asia Pacific
☞ South America- Brazil, Argentina, Colombia, Rest of South America
☞ Middle East and Africa- Saudi Arabia, UAE, Oman, Bahrain, Qatar, Kuwait, Israel

Chapter Outline:

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: key insights, key emerging trends, etc.

Chapter 3: Manufacturers competitive analysis, detailed analysis of Tyrosine Kinase Inhibitors manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 5 & 6: Revenue of Tyrosine Kinase Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: The main points and conclusions of the report.

Speak to Our Senior Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/tyrosine-kinase-inhibitors-market

Frequently asked questions:

➠ What is the global sales value, production value, consumption value, import and export of Tyrosine Kinase Inhibitors market?

➠ Who are the global key manufacturers of the Tyrosine Kinase Inhibitors Industry? How is their operating situation (capacity, production, sales, price, cost, gross, and revenue)?

➠ What are the Tyrosine Kinase Inhibitors market opportunities and threats faced by the vendors in the global Tyrosine Kinase Inhibitors Industry?

➠ Which application/end-user or product type may seek incremental growth prospects? What is the market share of each type and application?

➠ What focused approach and constraints are holding the Tyrosine Kinase Inhibitors market?

➠ What are the different sales, marketing, and distribution channels in the global industry?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Tyrosine Kinase Inhibitors Market Key Trends and Growth Drivers in Targeted Therapy | Key Players: Bayer Corporation, F. Hoffmann-La Roche Ltd, AstraZeneca, Novartis AG here

News-ID: 3818174 • Views:

More Releases from DataM intelligence 4 Market Research LLP

Autonomous Data Platform Market to Reach USD 14.96 Billion by 2032, Report by DataM Intelligence
Autonomous Data Platform Market to Reach USD 14.96 Billion by 2032, Report by Da …
Overview of the Autonomous Data Platform Market The Autonomous Data Platform (ADP) market is witnessing rapid growth, driven by digital transformation and the increasing need for real-time data analytics. ADPs use Artificial Intelligence (AI) and Machine Learning (ML) to automate data management, enabling businesses to make faster, data-driven decisions while minimizing human intervention. These platforms enhance operational efficiency, reduce errors, and allow enterprises to focus on strategic initiatives. ADPs are increasingly
Global 6G Technology Market to Reach USD 9.03 Billion by 2032, Report by DataM Intelligence
Global 6G Technology Market to Reach USD 9.03 Billion by 2032, Report by DataM I …
Overview of the Global 6G Technology Market The 6G technology market represents the next frontier in wireless communication, promising unprecedented advancements in speed, connectivity, and intelligence. Building upon the foundation laid by 5G, 6G aims to deliver peak data rates exceeding 1 terabit per second, ultra-low latency, and seamless integration of artificial intelligence (AI) and quantum-resistant encryption. These capabilities are set to revolutionize industries such as healthcare, automotive, manufacturing, and entertainment
Spinal Muscular Atrophy Treatment Market to Reach USD 20.06 Billion by 2033, Report by DataM Intelligence
Spinal Muscular Atrophy Treatment Market to Reach USD 20.06 Billion by 2033, Rep …
Overview of the Spinal Muscular Atrophy Treatment Market Spinal Muscular Atrophy (SMA) is a rare genetic disorder characterized by progressive muscle weakness, leading to severe physical disability and, in many cases, early death. The advent of innovative therapies has significantly altered the treatment landscape for SMA, offering hope for improved patient outcomes. Gene therapies, such as onasemnogene abeparvovec (Zolgensma), nusinersen (Spinraza), and risdiplam (Evrysdi), have demonstrated efficacy in increasing survival rates
United States Prime Editing and CRISPR Market 2025 | Growth Drivers, Key Players & Investment Opportunities
United States Prime Editing and CRISPR Market 2025 | Growth Drivers, Key Players …
Market Size and Growth Prime Editing and CRISPR Market is estimated to grow at a CAGR of 24.1% during the forecast period (2024-2031). Key Development: United States: Recent Industry Developments ✅ July 2025 - Prime Medicine announced an additional investment of up to $24 million from the Cystic Fibrosis Foundation to advance gene editing therapy targeting the G542X mutation, a prevalent cystic fibrosis-causing mutation with no current therapies. ✅ July 2025 - CRISPR

All 5 Releases


More Releases for Tyrosine

Global Tyrosine Supplements Market: A Comprehensive Overview
The global tyrosine supplements market was valued at approximately USD 1.2 billion in 2023 and is projected to reach around USD 2.8 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.9% from 2024 to 2030. Global Tyrosine Supplements Market Overview The global tyrosine supplements market is experiencing significant growth, driven by increasing consumer awareness of its cognitive and mood-enhancing benefits. Tyrosine, an amino acid, is widely
Bruton Tyrosine Kinase (BTK) Inhibitors Market
Introduction Bruton Tyrosine Kinase (BTK) inhibitors represent a critical class of medications in the treatment of various cancers, primarily blood-related malignancies. BTK is an enzyme crucial in the B-cell receptor signaling pathway, essential for B-cell development and function. This signaling pathway plays a central role in many types of blood cancers such as chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). By inhibiting BTK, these drugs effectively prevent the proliferation
Global Tyrosine Market 2015-2025 | Growing Opportunities and Trends in Tyrosine …
The Market Research Store has added the latest report on the Global Tyrosine Market which includes the historical data from 2015 to 2019 and has also precisely forecasted data from 2020 to 2025. The global Tyrosine market anticipates to showcase market value in terms of USD Million during the forecast period 2020 to 2025. According the research analyst the market will witness a steady growth during the coming years. Get Sample
Tyrosine Market Size, Share, Development by 2024
Global Info Research offers a latest published report on Tyrosine Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. The report contains 102 pages which highly exhibit on current market analysis scenario, upcoming as well as future opportunities, revenue growth, pricing and profitability. Click to view the full report TOC, figure and tables: https://www.globalinforesearch.com/global-tyrosine-market_p130094.html   Scope of the Report: The worldwide market for Tyrosine is
Glycyl Tyrosine Market SWOT Analysis 2018-2023
Future Market Reports on Global Glycyl Tyrosine 2018 Research Report presents a professional and complete analysis of Global Glycyl Tyrosine Market on the current market situation. The Global Glycyl Tyrosine Market 2018 report includes Glycyl Tyrosine market Revenue, market Share, Glycyl Tyrosine industry volume, market Trends, Growth aspects. It analyses the important factors of the Glycyl Tyrosine market based on present industry situations, Glycyl Tyrosine market demands, business strategies utilized
Cancer Tyrosine Kinase Inhibitors Market Cancer Tyrosine Kinase Clinical Pipelin …
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. The Journey: Genesis to Present of Tyrosine Kinase Inhibitors 2. Tyrosine Kinase: An Overview 3. Tyrosine Kinases Inhibitors: Promising Tools for Targeted Cancer Therapies 4. Types of Tyrosine Kinase Receptors 4.1 Epidermal Growth Factor Receptor 4.1.1 Types of Epidermal Growth Factor Receptor 4.1.2 Epidermal Growth Factor Receptor & Ligands 4.1.3